SARS Coronavirus Strain Diagnostic and Vaccine Development
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The development of sensitive and specific diagnostic reagents and vaccines for severe acute respiratory syndrome (SARS) is hindered by the lack of distinct variants of the SARS-associated coronavirus, which are necessary for effective detection and immunogenic compositions.
Innovation Solution
An isolated or purified strain of SARS-associated human coronavirus with specific mutations in its genome, characterized by a serine codon at position 23220, a glycine codon at position 25298, and an alanine codon at position 7918, derived from a sample collected in Hanoi, Vietnam, is used to develop nucleic acid molecules, proteins, and peptides as diagnostic reagents and vaccine components.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If a novel strain of SARS-associated coronavirus with specific mutations is used, then the sensitivity and specificity of diagnostic reagents and vaccines are improved, but the complexity of isolating and characterizing the strain increases
Solution Approach 1:
The patent creates copies of the viral genome through RT-PCR amplification, generating multiple copies of the RNA sequence that can be analyzed without requiring repeated isolation of the actual virus. This allows diagnostic development while avoiding the complexity of repeated viral isolation and characterization.
Solution Approach 2:
The patent performs preliminary characterization of the viral strain's genetic sequence, identifying specific mutations (such as the serine codon at position 23220) before developing diagnostic reagents. This preliminary genetic analysis enables targeted diagnostic development without needing to repeatedly isolate and characterize the physical virus.
2Reliability
If diagnostic reagents and vaccines are developed using the novel strain, then the reliability of SARS detection and protection is improved, but the time required for development and validation increases
Solution Approach 1:
The patent uses RT-PCR to generate copies of the viral RNA, enabling parallel development of multiple diagnostic reagents and vaccine candidates simultaneously from the same genetic material. This accelerates development while maintaining reliability through consistent use of the characterized strain's sequence.
Solution Approach 2:
The patent performs preliminary identification of unique genetic markers (specific codon positions and mutations) before diagnostic and vaccine development. This upfront characterization enables faster validation and reduces development time while ensuring reliability through targeted design based on confirmed strain-specific features.
Data Source
AI summary
The invention relates to a novel strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from a sample collected in Hanoi (Vietnam), reference number 031589, nucleic acid molecules originating from the genome of same, proteins and peptides coded by said nucleic acid molecules and, more specifically, protein N and the applications thereof, for example, as diagnostic reagents and/or as a vaccine.